Showing results (41-50 of 95) with videos related to
Sort By:
Pageof 10
Annals of Hematology|April 28, 2023
Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatmentTaku Kikuchi, Nobuhiro Tsukada, Moe Nomura, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 7, 2020
[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation]Kota Sato, Nobuhiro Tsukada, Junichiro Nashimoto, et al.European Journal of Haematology|November 17, 2019
The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myelomaKiyoshi Okazuka, Tadao Ishida, Junichiro Nashimoto, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[IgE-κ type multiple myeloma achieving complete response with novel agents]Tomomi Takei, Tadao Ishida, Masahiro Ikeda, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 4, 2024
[Retrospective analysis of allogeneic hematopoietic stem cell transplantation for multiple myeloma after myeloablative conditioning with 8 Gy of total body irradiation]Nobuhiro Tsukada, Moe Yogo, Kodai Kunisada, et al.Oncology Letters|January 25, 2019
Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity testTakumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, et al.Molecular and Clinical Oncology|August 10, 2019
Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapyYu Abe, Naoki Sakuyama, Tsuyoshi Sato, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 10, 2023
[A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy]Nobuhiro Tsukada, Yuki Oda, Moe Nomura, et al.Annals of Hematology|June 21, 2023
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple MyelomaYu Abe, Makoto Sasaki, Naoki Takezako, et al.Annals of Hematology|September 5, 2023
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodiesTaku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, et al.Pageof 10